Targeted RNA-sequencing assays: a step forward compared to FISH and IHC techniques?

Gaëlle Tachon1,2,3 | Ulrich Cortes3 | Sophie Richard2,4 | Sébastien Martin3 | Serge Milin4 | Camille Evrard5 | Corinne Lamour5 | Lucie Karayan-Tapon1,2,3

1Laboratoire de Neurosciences Expérimentales et Cliniques, Inserm U1084, Poitiers, France
2Université de Poitiers, Poitiers, France
3Laboratoire de Cancérologie Biologique, CHU de Poitiers, Poitiers, France
4Service d’Anatomo-Cytopathologie, CHU de Poitiers, Poitiers, France
5Service d’Oncologie, CHU de Poitiers, Poitiers, France

Correspondence
Gaëlle Tachon and Lucie Karayan-Tapon, UBM UF7730, Laboratoire de Cancérologie Biologique, CHU de Poitiers, 2 rue de la Milétrie, F-86022 Poitiers Cedex, France. Email: g.tachon@chu-poitiers.fr (G. T.) and l.karayan-tapon@chu-poitiers.fr (L.K.-T.)

Funding information
This research was supported by the ACSE program (Accès Sécurisé à des thérapies ciblées innovantes) of the “Institut National du Cancer”. These sponsors had no involvement in study design; in the collection, analysis, and interpretation of data; in the writing of the report; and in the decision to submit the article for publication.

Abstract

Introduction: ALK and ROS1 rearrangements are molecular targets of several tyrosine kinase inhibitors. RNA-sequencing approaches are regarded as the new standard for fusion gene detection, representing an alternative to standard immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) techniques.

Patients and Methods: We aimed to compare two recent amplicon-based RNA-sequencing techniques: FusionPlex® Alk Ret Ros1 v2 Kit (Archer®) with FHS-003Z-12—Human Lung Cancer Panel (Qiagen®) and assessed the accuracy of the data for therapy management. Thirty-seven formalin-fixed paraffin-embedded non-small cell carcinoma (NSCC) lesions initially explored by IHC and FISH were selected for RNA-sequencing analysis.

Results: Qiagen® and Archer® kits produced similar results and correctly identified 85.1% (23/27) and 81.5% (22/27) of IHC/FISH ALK- and ROS1-positive samples, respectively, and 100% (6/6) of the negative samples. With regard to the ambiguous IHC-positive/FISH-negative cases, RNA-sequencing confirmed 75% (3/4) of the FISH conclusion. Although not statistically significant, patients with common EML4-ALK variants presented shorter overall survival and progression-free survival compared with patients harboring rare variants.

Conclusion: Our findings assessed the implementation of RNA-sequencing approaches to explore ALK and ROS1 rearrangements from formalin-fixed paraffin-embedded samples. We highlighted the similarities between Qiagen® and Archer® kits in terms of handling time, cost, and outcomes. We confirmed the feasibility of molecular testing in routine organization and its possible use not only as an alternative for standard IHC and FISH techniques, but as a supplementary technique helping to classify discrepant cases.

Keywords
cancer genetics, lung cancer, medical genetics, next-generation sequencing
ROS proto-oncogene 1, receptor tyrosine kinase (ROS1), and anaplastic lymphoma kinase (ALK) rearrangements are present in approximately 2% and 5% of non-small cell lung cancers (NSCLCs), respectively. Fusion proteins resulting from these chromosomal rearrangements harbor strong oncogenic properties and are prime targets in cancer therapeutics. In this context, ALK tyrosine kinase inhibitors, such as crizotinib, were designed and approved by the FDA in 2011 for ALK-rearranged NSCLCs. In the same way, NSCLC patients with ROS1 rearrangements may benefit from crizotinib since 2016. Among these rearrangements involving different partners, EML4 is the most frequent ALK partner (77%) but several others have also been described. As over-activation of ALK tyrosine kinase or ROS1 tyrosine kinase is a prerequisite oncogenic event for cell transformation, the identification of fusion partners is not needed in kinase inhibitor therapy and is therefore rarely or never carried out. The standard methods currently used (fluorescence in situ hybridization [FISH] and immunohistochemistry [IHC]) to evaluate ROS1 and ALK rearrangement do not provide information about gene partners and the clinical significance of accurate gene fusions remains unclear.

IHC is a technique widely implemented in routine pathology laboratories and has proved to be an interesting prescreening test, which is inexpensive and easy to use. However, IHC is a targeted technique exploring ALK and ROS1 separately, therefore requiring a double amount of tumor material. In addition, IHC interpretation remains difficult, time-consuming in comparison with RNA-seq techniques, and requires the skills of a trained pathologist. Indeed, as long as the bioinformatic pipeline is well-configured, the RNA-seq will give a twofold response: presence or absence of gene fusion. On the contrary, IHC is not a binary test as positivity depends on the percentage of tumor cells stained and the intensity of the staining; it therefore requires more time for interpretation. The IASLC guidelines recommend IHC as the screening method for selecting specimens before FISH testing.

The admitted gold standard assay for detection of ALK and ROS1 rearrangements is the FISH technique using dual-labeled break-apart probes. Therefore, large amounts of tumor material must be available for both the IHC pres-screening test and the subsequent FISH testing. Comparative studies have reported high but not fully equivalent concordance rates between the two techniques. Strikingly, positive IHC cases have been reported without molecular rearrangement by FISH, and conversely. Such ambiguous cases are a challenge for therapeutic decisions.

Molecular approaches could be useful as a means of ascertaining discordant and ambiguous cases. Indeed, targeted RNA-sequencing (targeted RNA-seq) can achieve thorough detection and molecular characterization of several gene rearrangements concurrently, notably ALK fusions, and also ROS1 or NTRK fusions. Next-generation (NGS) targeted RNA-sequencing technology, with gene-specific primers designed in combination with universal primers, enables detection of any fused partner without “a priori” knowledge. Such information may have a predictive value for responses to targeted therapies. Several targeted RNA-seq assays have reached the market, with reliable results, but no comparative testing has been performed. In addition, unlike ALK rearrangement, detection of ROS1 rearrangement has never been fully assessed using latest generation assays.

To address these topics, we evaluated two targeted RNA-seq, the FusionPlex® Alk Ret Ros1 v2 Kit (Archer®) and the FHS-003Z-12—Human Lung Cancer Panel (Qiagen®). We aimed to determine the relevancy of these two methods for routine practice and to assess whether RNA-seq technology will ensure correct and reliable information for therapy management.

2 | MATERIALS AND METHODS

2.1 | Patients and samples

Forty-one NSCLC samples were selected based on routine molecular test results obtained at the Cancer Biology Department of Poitiers University Hospital between April 2014 and November 2017. The study was performed in accordance with French legislation (DC-2015-2449) and with the Declaration of Helsinki. Privacy of the data was ensured for all patients.

Among the 41 samples, four (9.8%) were excluded due to an insufficient amount of available RNA. Clinical data of the 37 selected patients include age, gender, smoking status, tumor stage, and sites, and are displayed in Table 1. Tumor samples were fixed in 4% formalin and embedded in paraffin (FFPE) according to standard procedure after surgical biopsy. Percentage of malignant cells was determined by trained pathologists of the university hospital. Histological data of the samples are available in Table S2.

Three control samples, HD784, HD796, and HD783, were purchased from Horizon Discovery, harboring well-characterized fusion transcripts (positive control) or no fusion (negative control). Two SureShot™ control samples from Archer® were also tested, harboring ROS1 rearrangement or no fusion, respectively.

2.2 | IHC testing

Samples were screened for ALK rearrangements by IHC staining using the D5F3 monoclonal antibody and, according to the Ventana protocol, adjusted to the laboratory constraints. ROS1 IHC was performed using prediluted D4D6 monoclonal antibody in accordance with Genemed instructions. The
percentage of ALK- or ROS1-positive cells was evaluated by trained pathologists as part of routine testing and scored as follows: score 0, no staining; 1+, faint cytoplasmic staining; 2+, moderate, smooth cytoplasmic staining; or 3+, intense granular cytoplasmic staining. All samples with scores of 1+, 2+, or 3+ for cytoplasmic staining in more than 10% of tumor cells were considered ALK-positive. All samples with cytoplasmic and membrane staining intensity of 1+, 2+, or 3+ were defined as ROS1-positive and were automatically directed to FISH screening, regardless of the % of stained cells.

### 2.3 | FISH testing

Vysis ALK Break Apart FISH probes© (Abbott Molecular) and ZytoLight® ROS1 SPEC Dual Color Break Apart were used for the detection of ALK and ROS1 rearrangements, respectively. Zeiss Axios Observer Z2 fluorescent microscope and ISIS software© (Meta System) were used for image acquisition. FISH results were evaluated by trained molecular biologists as part of routine molecular testing. Samples were considered ALK-positive if ≥15% of tumor cells showed isolated red signal(s) and/or split red and green signals. Polysomy was defined by an average copy number of ALK signal ≥6. FISH-positive cases for ROS1 rearrangements were defined by more than 15% split or single green signals. Evaluation was performed in preselected areas rich in tumor cells, on at least 50 tumor cells. Ambiguous cases were checked a second time and an additional count of 50 cells was carried out.

### 2.4 | RNA extraction

RNA was extracted from 1 to 4 FFPE sections of 10 µm using Maxwell 16 LEV RNA FFPE extraction kit according to manufacturer’s instructions. RNA samples were then quantified using QuantiFluor® RNA System on a Quansus ™ Fluorometer (Promega).

### 2.5 | Targeted NGS and data analysis

The Human Lung Cancer Panel kit (Qiagen) was designed to detect multiple gene rearrangements, among which ALK...
and ROS1 are major targets. This RNA-seq assay uses single primer extension and unique molecular barcodes to overcome traditional RNA-seq limitation and to ensure increased precision and accuracy. Briefly, a minimum of 20 ng of RNA was initially converted into a first cDNA strand, followed by second-strand synthesis to generate double-stranded cDNA (ds-cDNA). The ds-cDNA was then end-repaired, A-tailed, and ligated at 5’ end to a specific adapter containing unique molecular barcode and sample index. Single primer extension was then performed to ensure target enrichment. Universal PCR amplification was then carried out followed by the addition of a second sample index to achieve dual indexing.

Libraries were then quantified with a Quantus™ Fluorometer (Promega), pooled at equimolar concentrations, and sequenced on a Miseq sequencer (Illumina). Sequencing data were analyzed using QIAseq Targeted RNAseq Panel Analysis Software 2.0. Only high confidence fusion calls were analyzed using QIAseq Targeted RNAseq Panel Analysis Software 2.0. Only high confidence fusion calls were taken into account in this study.

FusionPlex® Alk Ret Ros1 v2 (Archer) was designed to exclusively detect ALK, RET, and ROS1 rearrangements with any other gene partner. A minimum of 50-ng RNA was used as input according to the manufacturer’s recommendations. The experiment was carried out as previously described. In brief, cDNA was first synthesized from the RNA using random priming, then end-repaired, followed by dA-tailing, and adapter ligation. Molecular barcoding and sample barcoding were both incorporated during FusionPlex library ligation. Two rounds of PCR amplification with gene-specific primers were then carried out. Lastly, libraries were quantified, pooled at equimolar concentration, and sequenced as described above. The fastQ files generated were analyzed using Archer analysis software v5.1. Only strong evidence fusions were taken into account for fusion calling.

Both assays were designed to detect fusions without “a priori” knowledge of the partner.

2.6 | Sanger sequencing

Exploration of ALK rearrangements in discordant cases was assessed directly by Sanger sequencing on sample libraries generated from Qiagen or Archer kits. Nested PCR was performed using the following primers: Forward P5: 5’-AATGATACGCGACACCAGCA-3’ (P5 region of adapter construct) with Reverse ALK20.1rc: 5’-CCTGTTGCTTCCGCTTGACATCA-3’ (ALK exon 20) for the first PCR and P5 5’-AATGATACGCGACACCAGCA-3’ with ALK20.2rc: 5’-CCATCTGCATGCTTGACAGCT-3’ for the nested PCR. Both PCR amplifications were performed as follows: 95°C for 15 minutes, 40 cycles of denaturation at 95°C for 20 seconds; annealing at 53°C for 30 seconds; extension at 72°C for 20 seconds, and a final extension at 72°C for 5 minutes. Samples were sequenced with a 3500Dx DNA Sequencer (Applied Biosystems).

3 | RESULTS

3.1 | IHC and FISH testing

Among 37 samples, 24 were considered ALK-positive and three samples were ROS1-positive based on at least IHC signals of 1+ associated with positive FISH results. Six ALK/ROS1-negative samples presented IHC scores from 0 to 1+ without ALK/ROS1 rearrangement detected by FISH. Finally, four ambiguous samples were defined as significant IHC signals (from 2+ to 3+) and with FISH-negative results. These results are summarized in Table 2.

3.2 | RNA-sequencing results obtained with reference samples

Three positive (HD784, HD796, and SureShot-ROS1) and two negative (HD783 and SureShot-Neg) controls, fully characterized and of high quality, were used to assess performance of the two methods. SureShot controls are RNA samples while HD784 and HD796 controls are cell lines-derived FFPE sections extracted and analyzed under the same conditions as patient samples, thereby ensuring the validity of the experiment from the extraction step.

HD784 harbors EML4-ALK, CCDC6-RET, and SLC34A2-ROS1 fusions. HD796 further contains TPM3-NTRK1 and ETV6-NTRK3 fusions. SureShot-ROS1 harbors SLC34A2-ROS1 fusion. HD783 and SureShot-Neg are negative controls containing none of the previous fusions.

Archer and Qiagen fusion assays successfully identified EML4-ALK, CCDC6-RET, and SLC34A2-ROS1 fusions. TPM3-NTRK1 fusion was detected only by Qiagen assay as the specific Archer FusionPlex® assay tested was not designed for NTRK1 detection. Neither of the two assays was designed for ETV6-NTRK3 detection. No false-positive was reported by either assay, thereby confirming their specificity (Table S1). To evaluate the robustness of both approaches, HD784-positive control was performed twice in two independent runs with freeze-thaw cycles of RNA. EML4-ALK, CCDC6-RET, and SLC34A2-ROS1 fusions were properly called in all cases with a high confidence index.

3.3 | RNA-sequencing results on characterized clinical samples

Among the 41 patients initially selected, 9.8% (4/41) could not be analyzed because of the insufficient amount of RNA obtained after extraction (<20 ng). Samples defined as positive according to IHC/FISH methods were correctly identified by the Qiagen fusion assay with 85% concordance.
(23/27) and by the Archer fusion assay with 82% concordance (22/27). No fusion transcripts were incorrectly called by either method (Table 2). The only discrepancy between the two assays involved one ALK rearrangement undetected by the Archer assay; however, this sample did not fulfill the quality assessment of the manufacturer (Ct > 30) and therefore would not have been explored under clinical practice. Quality assessment of original samples appears to be more

| Sample ID | IHC ALK | IHC ROS1 | FISH | ALK/ROS1 rearrangement | Transcript | Variant | Concordance |
|-----------|---------|----------|------|------------------------|------------|---------|-------------|
| Positive cases | E3837 | 3+ | ALK pos | EML4-ALK | E6:A20 | V3a/b | Yes |
| | E3959 | 3+ | ALK pos | EML4-ALK | E13:A20 | V1 | Yes |
| | E4428 | 3+ | ALK pos | EML4-ALK | E13:A20 | V1 | Yes |
| | E4513 | 2+ | ALK pos | EML4-ALK | E13:A20 | V1 | Yes |
| | E4559 | 2+ | ALK pos | EML4-ALK | E6:A20 | V3a/b | Yes |
| | E4883 | 2+ | ALK pos | EML4-ALK | E6:A18 | Unknown | Yes |
| | E4974 | 3+ | ALK pos | EML4-ALK | E6:A20 | V3a/b | Yes |
| | E4169 | 3+ | ALK pos | EML4-ALK | E6:A20 | V3a/b | Yes |
| | E3803 | 3+ | ALK pos | EML4-ALK | E6:A20 | V3a/b | Yes |
| | E3188 | 3+ | ALK pos | EML4-ALK | E6:A20 | V3a/b | Yes |
| | E3185 | 3+ | ALK pos | EML4-ALK | E6:A20 | V3a/b | Yes |
| | E3551 | 3+ | ALK pos | EML4-ALK | E6:A20 | V3a/b | Yes |
| | E2054 | 2+ | ALK pos | EML4-ALK | E6:A20 | V3a/b | Yes |
| | E4721 | 3+ | ALK pos | DCTN1-ALK | E26:A20 | Rare | Yes |
| | E3040 | 3+ | ALK pos | DCTN1-ALK | E26:A20 | Rare | Yes |
| | E3252 | 3+ | ALK pos | DCTN1-ALK | E26:A20 | Rare | Yes |
| | E5011 | 3+ | ALK pos | HIP1-ALK | E28:A20 | Rare | Yes |
| | E4115 | 2+ | ROS1 pos | CD74-ROS1 | E6:E34 | — | Yes |
| | E4268 | 3+ | ROS1 pos | CD74-ROS1 | E6:E34 | — | Yes |
| | E4610 | 2+ | ROS1 pos | SLC34A2-ROS1 | E6:E34 | — | Yes |
| | E4349 | 3+ | ALK pos | NEG | — | — | Yes |
| | E3276 | 2+ | ALK pos | NEG | — | — | Yes |
| | E2333 | 1+ | ALK pos | NEG | — | — | Yes |
| | E4170 | 3+ | ALK pos | NEG | — | — | Yes |
| Ambiguous cases | E5693 | 3+ | ALK neg | EML4-ALK | E13:A20 | V1 | Yes |
| | E5046 | 3+ | Polysomy | NEG | — | — | Yes |
| | E5193 | 2+ | ALK neg | NEG | — | — | Yes |
| | E5680 | 3+ | ALK neg | NEG | — | — | Yes |
| Negative cases | E4378 | 1+ | ROS1 neg | NEG | — | — | Yes |
| | E4598 | 1+ | ALK neg | NEG | — | — | Yes |
| | E4634 | 1+ | ALK neg | NEG | — | — | Yes |
| | E4674 | NEG | ALK neg | NEG | — | — | Yes |
| | E4720 | 1+ | ROS1 neg | NEG | — | — | Yes |
| | E5844 | 1+ | ALK Atypical pattern | NEG | — | — | Yes |

Abbreviations: FISH, fluorescence in situ hybridization; ID, identity; IHC, immunohistochemistry; NA, not amplified; neg, negative; pos, positive.
restricted for the Archer assay in comparison with the Qiagen assay.

Most fusions detected were commonly described fusions with 15 EML4-ALK (six E13:A20, six E6:A20, two E2:A20, and one E20:A20), one SLC34A2-ROS1, and two CD74-ROS1 variants. Interestingly, several infrequent transcripts were also detected, three samples showing DCTN1-ALK, one sample with HIP1-ALK, and two samples with rare EML4-ALK fusions (E6:A18 and E18:A20). All of these fusion transcripts were analyzed by both Qiagen and Archer analysis software (Table 2).

No fusion transcripts were reported for ALK-negative samples (E5844, E4598, E4624) or for ROS1-negative samples (E4378, E4720, E4674), nor were ALK fusions observed in ROS1-positive samples.

Four samples presented relevant IHC signals for ALK (2+ or 3+), although showing FISH-negative results (Table 2). In one sample (E5693), the IHC result was confirmed by both RNA-seq assays (25%, 1/4), in the other three samples (E5046, E5193, E5680) RNA-seq assays contradicted IHC results, thereby corroborating FISH conclusions (75%, 3/4). Consequently, therapeutic approaches were adjusted for patient E5693 according to RNA-seq findings. Among these ambiguous cases, it is worth noting that the E5046 strong IHC signal (3+) was correlated to ALK polysomy phenotype, disclosed by FISH. Significant ALK IHC staining of E5193 was established on 100 cells only (25% of tumor cells in the sample) and patient E5680 was an active smoker with large cell neuroendocrine carcinoma, not prone to present ALK rearrangement.

Another case (E5844), with faint IHC staining presented an unusual ALK FISH pattern with one fusion and one deleted (green) signal in most nuclei (Figure 1). In this case, no fusion was detected by RNA-seq assays. Therefore, RNA-seq assays are the most suitable techniques to explore such ambiguous cases as these assays are designed to detect any ALK or ROS1 fusion partner.

Four samples (E4349, E3276, E2333, E4170) showed discordant results despite FISH/IHC positive records (4/27, 14.8%), both RNA-seq assays indicating the absence of gene fusion (Table 2). In three samples (E4170, E2333, E4349), the amount of residual material allowed us to perform nested PCR on library products followed by Sanger sequencing analysis (Figure S1). All three patients showed EML4-ALK fusion transcripts, specifically variants 3 and 5 in two cases, whereas the fusion point was difficult to establish precisely in the third patient. Noticeably, E4349 and E4170 samples presented a low percentage of tumor cells (20%) and only a small amount of RNA had been extracted and was available for RNA-seq analysis (3.1 and 7.2 ng/µL, respectively), which may explain the false-negative result (Table S2). IHC of E2333 was performed despite a limited percentage of tumor cells (15%) and FISH positivity was set at the reference threshold of 15%. Therefore, it may be possible that remaining material for RNA-seq analysis contained less than 15% of tumor cells, which hampered efficient detection of rearrangements. The same postulate can be made for E3276, with only 30% tumor cells explored by FISH analysis and the positivity established at the reference threshold.

3.4 | Clinical relevance of rare fusion transcripts

Clinical data as well as progression-free survival and overall survival were available for 29 patients. Among them, 18 presented ALK rearrangements with an identified partner revealed by RNA-seq technology. Rare variants, with median overall survival of 66.6 months, appeared to be of better prognosis than common variants, namely variants 1 and 3, with median OS of 17.6 months, although these results did not reach statistical significance (P = .34) due to the reduced size of the cohort (Figure S2).

For instance, patient E4721 with a rare gene fusion DCTN1-ALK (E26:A20) received crizotinib at a dose of 250 mg twice a day as first-line therapy. A major response was observed by computed tomography scanning 3 months after initiation of therapy evidenced by a 60% decrease in tumor size and stabilization of bone lesions (Figure 2A). The overall condition of the patient significantly improved with no major side effects. Since then, the patient has been treated with crizotinib (18 months thus far). Patient E4883 presented a specific EML4-ALK rearrangement with breakpoint of the ALK gene occurring ahead of exon 18, (instead of exon 20, as usually described), preserving the tyrosine kinase domain. This patient received ceritinib, 5×150 mg, as second-line therapy after a first-line of crizotinib was discontinued due to hepatotoxicity. A dramatic response to targeted therapy was observed with major regression of the primary lung lesions and liver metastases (Figure 2B).

Finally, patient E5011 presented HIP1-ALK rearranged adenocarcinoma with metastases spreading to the lung, meningitis, and pericardium at diagnosis. This patient refused encephal radiotherapy but accepted targeted therapy based on crizotinib orally at a dose of 250 mg twice daily. The progression of the disease was stopped and lesions have been stabilized for now (13 months thus far) (Figure 2C).

3.5 | Technical comparison of existing methods

IHC is easily automatizable, does not require additional steps such as RNA extraction, and requires a limited amount of tumor material (two FFPE sections of 4 µmol/L). The method is cost-friendly and time-saving even though two independent experiments have to be run (one for each protein explored). However, IHC provides overall information on protein expression but not on the mechanisms involved
FIGURE 1  IHC and FISH analyses of ALK rearrangement of E5844 tumor. A, Photograph of IHC cytoplasmic staining in more than 10% of tumor cells at a score of 1+ (×10). B, Photograph of FISH showing atypical pattern of fused signal associated with isolated green signal (×100). FISH, fluorescence in situ hybridization; IHC, immunohistochemistry.

FIGURE 2  Representative images showing the presence of ALK rearrangements in E4721 (A), E4883 (B), and E5011 (C) patients. All left panels show representative images of rearranged tumors with either a classic break-apart pattern with one fusion signal and two split red and green signals or a less common pattern with isolated red signal(s) combined with fused signals (×100). Representative medium (2+) to strong (3+) IHC staining are shown in middle panels. Thoracic computed tomography scans of patients before and after targeted therapy are shown in the right panels and schematic representations of the fusion transcript for each case are presented below the three panels. IHC, immunohistochemistry.
(gene amplification, rearrangement). In addition, interpretation of results may be difficult due to semiquantitative scoring of the signal, which does not allow definition of a proper threshold between negative and positive samples (Table 3).

Similarly, FISH can also be automated, does not require DNA extraction, and can be achieved with low input of tumor material. FISH provides the advantage of differentiating between gene rearrangements, polysomy, and amplification processes and therefore gives more concise information for therapy purposes. To that extent, although the clinical significance of ALK amplification and polysomy remains uncertain, these alterations have been reported to be involved in resistance to crizotinib. However, this method neither identifies gene partners nor provides information on chromosomal rearrangements.

FusionPlex® Alk Ret Ros1 v2 (Archer) and Human Lung Cancer Panel (Qiagen) are very similar targeted RNA-seq technologies from two different suppliers. Both assays can detect the accurate fusion transcripts and can explore several genetic rearrangements concurrently. While human Lung Cancer Panel investigates more genes than FusionPlex® Alk Ret Ros1 v2 assay (27 vs 3), both suppliers provide customized services for extending panels of target genes. The main disadvantages of RNA-seq assays compared to IHC and FISH are the extra cost and increased processing time for library preparation and sequencing.

### DISCUSSION

Detection of ALK and ROS1 rearrangements by IHC pre-screening and FISH confirmation is the standard process for identifying patients with NSCLC eligible for treatment with tyrosine kinase inhibitors. FISH/IHC discordances are common in routine practice and decision-making on treatment with targeted therapies remains complicated for these patients. Recent studies have suggested that IHC testing alone may provide a better estimate of crizotinib response than FISH. An observational study from the European Society for Medical Oncology reported that IHC testing was an ideal, robust, and accurate primary procedure to determine access to targeted therapy as long as quality testing and validation assays are performed. In compliance with this, patients from our cohort with strong IHC staining (2+ or 3+) could have received targeted therapy without FISH exploration. However, 75% of these patients were actually negative according to FISH analysis and did not present any ALK rearrangement according to the two independent RNA-seq assays. IHC results were confirmed by RNA-seq assays for one patient only (1/4). Hence, this study suggests that RNA-seq analysis could be of major interest in settling FISH/IHC discordances. These observations are consistent with previous studies. For example, Vollbrecht et al. investigated 18 unequivocal and 15 equivocal samples through RNA-seq-based analysis with discordant results between FISH and IHC and identified three false-positive FISH samples. Pekar-Zlotin et al investigated the IHC and FISH profiles of 51 lung adenocarcinomas and confirmed discrepancies by NGS analysis. The authors identified false-negative FISH samples and concluded that ALK testing should initially be based on IHC and/or NGS-based methods instead of FISH testing. Finally, Jang et al. conducted a similar study and found that ALK FISH results were false-positive in three out of four FISH-positive/IHC-negative cases and confirmed that NGS approach was most effective in detection of ALK rearrangements.
Therefore, molecular approaches seem to be more reliable than FISH in detection of fusion genes and may become the new gold standard. In our study, RNA-seq assays failed to detect four rearranged samples, and three of them were confirmed by Sanger experiment (14.8%, 4/27). Both companies reported technical sensitivity of 90%-95%, nevertheless established on internal control samples. Our study showed the sensitivity of these techniques on real case samples and in routine laboratory conditions, although the number of samples was limited. Recent publications have also confirmed the considerable but not complete correlation between IHC/FISH and RNA-seq explorations. In a cohort of 53 samples, McLeer–Florin et al. reported RNA-seq sensitivity of 80%. Yoshida et al. showed that tumors with EML4-ALK variant preferentially responded to crizotinib compared with other variants. In our study, no significant differences were observed in overall survival and progression-free survival when comparing rare fusion genes or rare EML4-ALK variants with most common variants. Although not significant, there was a clear trend toward longer OS and PFS for patients with rare EML4-ALK variants. The clinical impact of the different fusion partners remains to be determined along with its implications for therapeutic management.

Lastly, despite the higher cost and processing time, simultaneous analysis of several fusion genes represents a major advantage of the NGS methods. A recent study has shown that patients with NTRK1-rearranged NSCLCs can benefit from entrectinib-based therapy. Recently, the FDA approved larotrectinib for solid tumors with NTRK gene fusions. Another study has shown the good response of RET-rearranged adenocarcinoma to cabozantinib, a multi-kinase inhibitor. While fusion genes are rare events in lung adenocarcinoma, their presence is an indicator of possible targeted therapy. Moreover, fusion genes have also been reported in invasive mucinous adenocarcinoma and squamous and small-cell lung cancers, and their exploration may soon be required in therapeutic management. Molecular pathology laboratories have already started receiving requests for exploration of various new fusions, for example, NTRK in lung cancer, FGFR2 in colorectal cancer, BRAF in pilocytic astrocytoma. Therefore, instead of developing, validating, and certifying new IHC/FISH tests for all new markers, it might be preferable to implement RNA-seq testing to explore all of them concurrently. Moreover, most genomic companies offer customized solutions for the design of RNA-seq panels. Therefore, if a new fusion marker of interest is revealed for cancer therapy or prognosis, it can easily be added into the existing panel.

### 5 | CONCLUSION

In conclusion, while RNA-seq tests for ALK and ROS1 fusion detection were achievable and provided full information regarding the gene partner, sensitivity did not reach 100% and several samples could not be analyzed due to low RNA amount. QIAsel human lung cancer targeted RNAscan panel and FusionPlex® Alk Ret Ros1 v2 required similar operating practices and provided similar results with FFPE samples. Currently, in the absence of requirements for partner-gene information prior to targeted therapy, RNA-seq assays might be restricted to settling discordant cases with equivocal IHC/FISH results.

### ACKNOWLEDGMENTS

We thank Jeffrey Arsham, an American translator, for having reviewed and revised the original English-language text. We also thank Sebastien Martin for his technical assistance as well as Gwenaelle Merrien for her secretarial assistance.

### CONFLICT OF INTEREST

None declared.
DATA AVAILABILITY STATEMENT

The data that support the findings of this study are available on request from the corresponding author.

ORCID

Gaëlle Tachon https://orcid.org/0000-0002-0391-7143

REFERENCES

1. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007;448(7153):561-566.
2. Sabir S, Yeoh S, Jackson G, Bayliss R. EML4-ALK variants: biological and molecular properties, and the implications for patients. Cancers (Basel). 2017;9:1118.
3. Hallberg B, Palmer RH. The role of the ALK receptor in cancer biology. Ann Oncol. 2016;27(suppl_3):iii4-iii15.
4. Li Y, Zhang T, Zhang J, et al. Response to crizotinib in advanced ALK-rearranged non-small cell lung cancers with different ALK-fusion variants. Lung Cancer. 2018;118:128-133.
5. Savic S, Diebold J, Zimmermann A-K, et al. Screening for ALK in non-small cell lung carcinomas: 5A4 and D5F3 antibodies perform equally well, but combined use with FISH is recommended. Lung Cancer. 2015;89(2):104-109.
6. Ilie MI, Bence C, Hofman V, et al. Discrepancies between FISH and immunohistochemistry for assessment of the ALK status are associated with ALK ‘borderline’-positive rearrangements or a high copy number: a potential major issue for anti-ALK therapeutic strategies. Ann Oncol. 2015;26(1):238-244.
7. Lindeman NI, Cagle PT, Beasley MB, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Mol Diagn. 2013;15(4):415-453.
8. Yatabe Y. ALK FISH and IHC: you cannot have one without the other. J Thorac Oncol. 2015;10(4):548-550.
9. Pekar-Zlotin M, Hirsch FR, Soussan-Gutman L, et al. Fluorescence in situ hybridization, immunohistochemistry, and next-generation sequencing for detection of EML4-ALK rearrangement in lung cancer. Oncologist. 2015;20(3):316.
10. Demidova I, Grinevich V, Avdalian A, et al. Detection of ALK rearrangements in 4002 Russian patients: the utility of different diagnostic approaches. Lung Cancer. 2017;103:17-23.
11. Vendrell JA, Taviaux S, Béganton B, et al. Detection of known and novel ALK fusion transcripts in lung cancer patients using next-generation sequencing approaches. Sci Rep. 2017;7(1):12510.
12. Conde E, Hernandez S, Prieto M, Martinez R, Lopez-Rios F. Profile of Ventana ALK (D5F3) companion diagnostic assay for non-small-cell lung carcinomas. Expert Rev Mol Diagn. 2016;16(6):707-713.
13. Cha YJ, Lee JS, Kim HR, et al. Screening of ROS1 rearrangements in lung adenocarcinoma by immunohistochemistry and comparison with ALK rearrangements. PLoS ONE. 2014;9(7):e103333.
14. Thunnissen E, Bubendorf L, Dietel M, et al. EML4-ALK testing in non-small cell carcinomas of the lung: a review with recommendations. Virchows Arch. 2012;461(3):245-257.
15. Zito Marino F, Rocco G, Morabito A, et al. A new look at the ALK gene in cancer: copy number gain and amplification. Expert Rev Anticancer Ther. 2016;16(5):493-502.
16. Bubendorf L, Böttner R, Al-Dayer F, et al. Testing for ROS1 in non-small cell lung cancer: a review with recommendations. Virchows Arch. 2016;469(5):489.
17. Shirouguchi K, Jia TZ, Sims PA, Xie XS. Digital RNA sequencing minimizes sequence-dependent bias and amplification noise with optimized single-molecule barcodes. Proc Natl Acad Sci USA. 2012;109(4):1347.
18. Rodig SJ, Mino-Kenudson M, Dacic S, et al. Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the Western population. Clin Cancer Res. 2009;15(16):5216.
19. van der Wekken AJ, Pelgrim R, ‘t Hart N, et al. Dichotomous ALK-IHC is a better predictor for ALK inhibition outcome than traditional ALK-FISH in advanced non-small cell lung cancer. Clin Cancer Res. 2017;23(15):4251-4258.
20. van der Wekken AJ, Kok K, Groen H. Is alectinib the first line therapy in ALK-rearranged advanced non-small cell lung cancer? J Thorac Dis. 2018;10(suppl 18):S2130.
21. Cabillic F, Hofman P, Ilie M, et al. ALK IHC and FISH discordant results in patients with NSCLC and treatment response: for discussion of the question—to treat or not to treat? ESMO Open. 2018;3(6):e000419.
22. Vollbrecht C, Lenze D, Hummel M, et al. RNA-based analysis of ALK fusions in non-small cell lung cancer cases showing IHC/FISH discordance. BMC Cancer. 2018;18:1158.
23. Jang JS, Wang X, Vedell PT, et al. Custom gene capture and next generation sequencing to resolve discordant ALK status by FISH and IHC in lung adenocarcinoma. J Thorac Oncol. 2016;11(11):1891.
24. McLaren-Florin A, Duruisseaux M, Pinsolle J, et al. ALK fusion variants detection by targeted RNA-next generation sequencing and clinical responses to crizotinib in ALK-positive non-small cell lung cancer. Lung Cancer. 2018;116:15-24.
25. Letovanec I, Finn S, Zygoura P, et al. Evaluation of NGS and RT-PCR methods for ALK rearrangement in European NSCLC patients: results from the European Thoracic Oncology Platform Lungscape Project. J Thorac Oncol. 2018;13(3):413-425.
26. Yoshida T, Oya Y, Tanaka K, et al. Differential crizotinib response duration among ALK fusion variants in ALK-positive non-small-cell lung cancer. J Clin Oncol. 2016;34(28):3383-3389.
27. Farago AF, Le LP, Zheng Z, et al. Durable clinical response to entrectinib in NTRK1-rearranged non-small cell lung cancer. J Thorac Oncol. 2015;10(12):1670-1674.
28. Driton A, Wang L, Hasanovic A, et al. Response to cabozantinib in patients with RET fusion-positive lung adenocarcinoma. Cancer Discov. 2013;3(6):630-635.
29. Nakao T, Tsuta K, Ichikawa H, et al. Druggable oncogene fusions in invasive mucinous lung adenocarcinoma. Clin Cancer Res. 2014;20(12):3087-3093.
30. Weiss J, Sos ML, Seidel D, et al. Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med. 2010;2(62):62ra93.
31. Kohno T, Nakaoku T, Tsuta K, et al. Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer. *Transl Lung Cancer Res*. 2015;4(2):156-164.

**SUPPORTING INFORMATION**

Additional supporting information may be found online in the Supporting Information section at the end of the article.

**How to cite this article:** Tachon G, Cortes U, Richard S, et al. Targeted RNA-sequencing assays, a step forward compared to FISH and IHC techniques? *Cancer Med*. 2019;8:7556-7566. [https://doi.org/10.1002/cam4.2599](https://doi.org/10.1002/cam4.2599)